Literature DB >> 16575403

Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer.

Shigeto Ueda1, Kazuo Hatsuse, Hitoshi Tsuda, Sho Ogata, Nobuaki Kawarabayashi, Toshimichi Takigawa, Takahiro Einama, Daisaku Morita, Kazuhiko Fukatsu, Yoshiaki Sugiura, Osamu Matsubara, Hidetaka Mochizuki.   

Abstract

The insulin-like growth factor receptor type 1 (IGF1R) and epidermal growth factor receptor (EGFR) are reportedly overexpressed in pancreatic cancer. However, the correlation between activated EGFR and IGF1R and their clinicopathological implications still remain unclear. The cellular localization and overexpression of IGF1R and EGFR were investigated immunohistochemically in primary invasive ductal pancreatic carcinomas obtained from 74 patients who underwent radical surgical resection. We also compared the status of IGF1R and EGFR overexpression between primary tumors and hepatic metastatic tumors obtained from 44 autopsied patients. Among the 74 surgically resected primary tumors, cytoplasm- and membrane-dominant EGFR overexpression was detected in 22 (30%) and 7 (9%), respectively, whereas cytoplasm- and membrane-dominant IGF1R overexpression was detected in 8 (11%) and 28 (38%), respectively. Membrane-dominant EGFR and cytoplasm-dominant IGF1R were more frequent in lower-grade tumors and correlated with favorable prognosis, whereas cytoplasm-dominant EGFR and membrane-dominant IGF1R were more frequent in higher-grade tumors and correlated with poor prognosis. In 36 autopsy specimens of pancreatic tumor with concurrent overexpression of IGF1R and EGFR, there was an inverse correlation between the IGF1R and EGFR localization patterns (P = 0.001). In the hepatic metastatic tumors obtained by autopsy, the incidences of both IGF1R and EGFR overexpression were much higher than in the surgically resected primary tumors. More than half of the autopsy cases consistently showed membrane-dominant EGFR expression in both the primary tumor and hepatic metastases, whereas IGF1R expression showed considerable variation. Crosstalk between differently localized IGF1R and EGFR might play a role in determining the biological aggressiveness of pancreatic cancer, although their cellular localization may often alter during the process of metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575403     DOI: 10.1038/modpathol.3800582

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Authors:  Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 3.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

4.  New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.

Authors:  Donghui Li; James L Abbruzzese
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

5.  Both epidermal growth factor and insulin-like growth factor receptors are dispensable for structural intestinal adaptation.

Authors:  Raphael C Sun; Jose L Diaz-Miron; Pamela M Choi; Joshua Sommovilla; Jun Guo; Christopher R Erwin; Brad W Warner
Journal:  J Pediatr Surg       Date:  2015-03-14       Impact factor: 2.545

Review 6.  Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.

Authors:  David N Boone; Adrian V Lee
Journal:  Crit Rev Oncog       Date:  2012

7.  Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.

Authors:  Sandra Pérez-Torras; Anna Vidal-Pla; Rosa Miquel; Vanessa Almendro; Laureano Fernández-Cruz; Salvador Navarro; Joan Maurel; Neus Carbó; Pere Gascón; Adela Mazo
Journal:  Cell Oncol (Dordr)       Date:  2011-06-17       Impact factor: 6.730

8.  Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

9.  Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma.

Authors:  Takahiro Einama; Shigeto Ueda; Hitoshi Tsuda; Kazuhiro Ogasawara; Kazuo Hatsuse; Osamu Matsubara; Satoru Todo; Junji Yamamoto
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

Review 10.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.